Alkermes Plc (ALKS)

Jul 24, 2025

What drives Alkermes plc stock priceUnprecedented growth rates - Autocar Professional

Jul 24, 2025

Jul 24, 2025

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Jul 24, 2025

Jul 23, 2025

Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - BioCentury

Jul 23, 2025

Jul 23, 2025

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN

Jul 23, 2025

Jul 23, 2025

What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Jul 22, 2025

Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - TradingView

Jul 22, 2025

Jul 22, 2025

Alkermes stock holds steady as H.C. Wainwright maintains Neutral rating By Investing.com - Investing.com UK

Jul 22, 2025

Jul 21, 2025

Alkermes Announces Positive Phase 2 Study Results - TipRanks

Jul 21, 2025

Jul 21, 2025

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com

Jul 21, 2025

Jul 21, 2025

Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus

Jul 21, 2025

Jul 21, 2025

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl

Jul 21, 2025

Jul 21, 2025

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl

Jul 21, 2025

Jul 21, 2025

Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive

Jul 21, 2025

Jul 21, 2025

Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Jul 21, 2025

Jul 21, 2025

Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK

Jul 21, 2025

Jul 21, 2025

Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq

Jul 21, 2025

Jul 21, 2025

Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener

Jul 21, 2025

Jul 21, 2025

Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK

Jul 21, 2025

Jul 21, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Jul 21, 2025

Jul 21, 2025

Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study - Sleep Review

Jul 21, 2025

Jul 20, 2025

Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛

Jul 20, 2025

Jul 19, 2025

10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey

Jul 19, 2025

Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India

Jul 17, 2025

Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% - Investing.com

Jul 17, 2025

Jul 15, 2025

Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest

Jul 15, 2025

Jul 15, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener

Jul 15, 2025

Jul 15, 2025

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga

Jul 15, 2025

Jul 15, 2025

Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus

Jul 15, 2025

Jul 14, 2025

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Jul 14, 2025